US Patent

US10016403 — Sublingual fentanyl spray

Formulation · Assigned to Insys Development Co Inc · Expires 2027-01-25 · 1y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects sublingual formulations containing fentanyl, a pharmaceutically acceptable salt, or derivative thereof, for patient administration.

USPTO Abstract

The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.

Drugs covered by this patent

Duragesic (fentanyl) · Johnson & Johnson (Janssen Pharmaceutica)

Patent Metadata

Patent number: US10016403
Jurisdiction: US
Classification: Formulation
Expires: 2027-01-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Insys Development Co Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.